DAC-002 / Helioson Pharmaceutical - LARVOL DELTA

DAC-002, a novel IKZF1/3 MGD-CD38 degrader-antibody conjugate for MM treatment (AACR 2026) - "Notably, since IKZF1/3 are essential transcription factors (TFs) for the differentiation of B and T lymphocytes, single-agent IMiD therapy is hampered by a limited therapeutic window: as next-generation IMiDs (e.g., iberdomide, mezigdomide, cemsidomide) exhibit enhanced IKZF1/3 degradation activity, the incidence of grade ≥ 3 hematologic treatment-emergent adverse events (TEAEs) is correspondingly elevated...Degrader-Antibody conjugates (DACs) was generated by conjugation of CY001-80 (payload) to daratumumab monoclonal antibody (anti-CD38) using an optimized cleavable linker...In summary, DAC-002 is an highly potent IKZF1/3 MGD-CD38 DAC. In MM-H929 xenograft tumor model, DAC-002 treatment lead to robust tumor growth inhibition. No obvious safety concerns were observed in the preliminary NHP toxicology study."

IO biomarker • Late-breaking abstract • Hematological Malignancies • Multiple Myeloma • Oncology • IKZF1